News and Announcements

Compugen to Enter Research Collaboration with Mount Sinai on Novel Myeloid Immuno-Oncology Targets
November 3, 2017

Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the initiation of a multi-year cancer immunotherapy research collaboration with Continue reading

2017 Inventor of the Year Award
October 31, 2017

Yiannis Ioannou, PhD, was honored with the 2017 Mount Sinai Inventor of the Year Award, presented at the SinaInnovations Awards Ceremony on October 16.

Dr. Ioannou's work in lysosomal storage diseases Continue reading

Mount Sinai Health System Partners With Contessa Health to Expand Hospital-Level Care at Home Program
October 18, 2017

The Mount Sinai Health System announced today that it has partnered with Contessa Health, an innovative health care company that manages acute-care services at home through prospective bundled payment arrangements, Continue reading

InDevR Licenses Mount Sinai Influenza Antibodies for VaxArray® Neuraminidase Potency Assay
September 22, 2017

​​InDevR, a Boulder-based progressive analytical technology and life science instrumentation company today announced that it has entered into an exclusive, world-wide license agreement for monoclonal antibodies developed by scientists at Continue reading

Technology from a Mount Sinai Startup (Cardea Sciences) That Will Improve Outcomes for Cardiac Patients Wins the NYC Life Science Innovation Showcase
July 18, 2017

July 18, 2017 - Technology for identifying at-risk atrial fibrillation (AFib) patients was chosen as the winner of the inaugural Alexandria LaunchLabs Scholarship Award, which recognizes excellence in health care Continue reading

Breathing in a New Gene Therapy to Treat Pulmonary Hypertension
July 13, 2017

June 12, 2017- Mount Sinai has partnered with Theragene Pharmaceuticals, Inc. to advance a novel airway-delivered gene therapy for treating pulmonary hypertension (PH), a form of high blood pressure in Continue reading

Mount Sinai, Pfizer Renew Research Collaboration, Building on Strong Foundation
June 28, 2017

June 28, 2017 - The Icahn School of Medicine at Mount Sinai and Pfizer Inc.’s Centers for Therapeutic Innovation (CTI) recently announced the renewal of an agreement designed to identify and Continue reading

Treating Depression with Software: Technology from Mount Sinai Steps into the Digital Healthcare Universe
June 7, 2017

June 7, 2017 - A treatment for depression using Emotional Faces Memory Task (EFMT), a technology originally developed by two Mount Sinai researchers, resulted in a significantly greater reduction of major Continue reading

Engineering New Anti-Cancer Drugs from Old Medicines
May 25, 2017

May 25, 2017 - An interdisciplinary collaboration including 45 researchers has discovered a new class of drug candidates that activates the tumor suppressor protein PP2A. These new compounds have been shown Continue reading

Mount Sinai and Stony Brook Announce Affiliation
August 11, 2016

August 11, 2016 - Stony Brook Medicine and the Mount Sinai Health System today announced that they are entering into an affiliation agreement that includes collaboration on research, academic programs and Continue reading

Four NCI Cancer Centers Announce Landmark Research Consortium and Collaborations with Celgene
June 22, 2016

June 22, 2016 - Today, The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Continue reading

Mount Sinai and Galmed Pharmaceuticals to Collaborate in an Investigator Initiated Phase IIa Trial to Evaluate the Effect of AramcholTM in Combination with Vitamin D for the Treatment of Patients with Fibrotic Nonalcoholic Fatty Liver Disease
May 3, 2016

May 3, 2016 - Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of a once-daily, oral therapy for the treatment of liver Continue reading

Takeda Launches Multi-Year Research Partnership with Leading Inflammatory Bowel Disease Institutions
March 31, 2016

March 31, 2016 - Takeda Pharmaceuticals U.S.A., Inc. ("Takeda"), today announced a multi-year research partnership with two world leading academic centers with a proven long-term commitment to inflammatory bowel disease (IBD) Continue reading

Dual Therapeutics Announces Oncology Strategic Collaboration with Bristol-Myers Squibb
January 8, 2016

January 8, 2016 - Dual Therapeutics, LLC (“Dual Therapeutics”) today announced a strategic collaboration with Bristol-Myers Squibb (NYSE: BMY) to advance small molecule compounds for the treatment of cancer and Continue reading

“Dark Matter” in Cancer Genome Prompts Immune Response
December 7, 2015

December 7, 2015 - Researchers at the Icahn School of Medicine at Mount Sinai have discovered a group of non-coding RNA molecules in cancer cells that sets off an immune response Continue reading

Mount Sinai Innovation Partners Launches New Web Resources for Faculty
December 3, 2015

Mount Sinai Innovation Partners, MSIP, is a business unit of the health system that facilitates the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships. Continue reading

Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
November 10, 2015

November 10, 2015 - Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel therapeutic approaches for patients with inflammatory bowel disease (IBD), Continue reading

‘JEDI’ Technology Awakens New Understanding of How Immune System Works
November 4, 2015

November 4, 2015 - When it comes to fending off disease and helping prevent people from falling ill, the body's immune system -- armed with T-cells that help eliminate cancer cells, Continue reading

Mount Sinai Innovation Awards
October 25, 2015

On Monday, October 26, 2015, Mount Sinai Innovation Partners sponsored the first ever Mount Sinai Innovation Awards Ceremony, celebrating five new honors that recognize significant contributions in biomedical education and industry.

Through Continue reading

Celmatix Launches Personalized Reproductive Medicine (PReM) Initiative to Decode Fertility Potential
October 19, 2015

October 19, 2015 - Celmatix, a personalized medicine company focused on fertility and women’s health, today announced the launch of the Personalized Reproductive Medicine (PReM) Initiative, an alliance created to investigate Continue reading